Swen Hoelder

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 45(Granted Patents)

Company Filing History:

15 out of 263

Cancer Research Technology Limited

patents

3 out of 51

The Institute of Cancer Research: Royal Cancer Hospital

patents

1 out of 24

The Institute of Cancer Research

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486285 - BCL6 inhibitors (2025-12-02),

2. 12110286 - Benzimidazolone derived inhibitors of BCL6 (2024-10-08),

3. 11897877 - Inhibitor compounds (2024-02-13),

4. 11512095 - BCL6 inhibitors (2022-11-29),

5. 11161839 - 2-quinolone derived inhibitors of BCL6 (2021-11-02),

6. 11046688 - Inhibitor compounds (2021-06-29),

7. 10479788 - Compounds that inhibit MPS1 kinase (2019-11-19),

8. 10399974 - N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors (2019-09-03),

9. 10188642 - Pharmacologically active compounds (2019-01-29),

10. 9902721 - N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors (2018-02-27),

11. 9895364 - Pharmacologically active compounds (2018-02-20),

12. 9890157 - Inhibitor compounds (2018-02-13),

13. 9834552 - Inhibitor compounds (2017-12-05),

14. 9409907 - Inhibitor compounds (2016-08-09),

15. 9334286 - Pharmacologically active compounds (2016-05-10),

Title: Unveiling the Inventive Mind of Swen Hoelder in London

Introduction:

Swen Hoelder, a distinguished inventor based in London, UK, has made significant contributions to the field of medicine and oncology. With an impressive portfolio of 13 patents, Hoelder's work has centered on developing innovative compounds for the treatment and prevention of proliferative diseases, particularly cancer.

Latest Patents:

Hoelder's latest patents showcase his expertise in developing compounds that target specific pathways involved in cancer progression. His groundbreaking work includes the development of inhibitor compounds that target the Monospindle 1 (Mps1) kinases, as well as BCL6 inhibitors. These compounds have shown promising results in inhibiting key proteins associated with cancer development, paving the way for novel therapeutic interventions.

Career Highlights:

Having worked with esteemed institutions such as Cancer Research Technology Limited and The Institute of Cancer Research: Royal Cancer Hospital, Swen Hoelder has gained invaluable experience in the field of oncology research. His dedication to developing innovative solutions for the treatment of cancer has earned him recognition among his peers and in the scientific community.

Collaborations:

Throughout his career, Swen Hoelder has collaborated with esteemed researchers and scientists in the field of oncology. Notable coworkers include Julian Blagg and Butrus Atrash, who have contributed to the success of Hoelder's research endeavors. Through collaborative efforts, Hoelder has been able to leverage diverse expertise and insights to advance his innovative research projects.

Conclusion:

Swen Hoelder's pioneering work in the development of novel compounds for the treatment of cancer underscores his commitment to pushing the boundaries of scientific discovery. His patents stand as a testament to his ingenuity and dedication to making a meaningful impact in the fight against proliferative diseases. As an inventor, Hoelder continues to inspire others in the field with his innovative approach to tackling complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.